Cargando…
SUMOtherapeutics for Ischemic Stroke
The small, ubiquitin-like modifier (SUMO) is a post-translational modifier with a profound influence on several key biological processes, including the mammalian stress response. Of particular interest are its neuroprotective effects, first recognized in the 13-lined ground squirrel (Ictidomys tride...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221934/ https://www.ncbi.nlm.nih.gov/pubmed/37242456 http://dx.doi.org/10.3390/ph16050673 |
_version_ | 1785049575328841728 |
---|---|
author | Karandikar, Paramesh Gerstl, Jakob V. E. Kappel, Ari D. Won, Sae-Yeon Dubinski, Daniel Garcia-Segura, Monica Emili Gessler, Florian A. See, Alfred Pokmeng Peruzzotti-Jametti, Luca Bernstock, Joshua D. |
author_facet | Karandikar, Paramesh Gerstl, Jakob V. E. Kappel, Ari D. Won, Sae-Yeon Dubinski, Daniel Garcia-Segura, Monica Emili Gessler, Florian A. See, Alfred Pokmeng Peruzzotti-Jametti, Luca Bernstock, Joshua D. |
author_sort | Karandikar, Paramesh |
collection | PubMed |
description | The small, ubiquitin-like modifier (SUMO) is a post-translational modifier with a profound influence on several key biological processes, including the mammalian stress response. Of particular interest are its neuroprotective effects, first recognized in the 13-lined ground squirrel (Ictidomys tridecemlineatus), in the context of hibernation torpor. Although the full scope of the SUMO pathway is yet to be elucidated, observations of its importance in managing neuronal responses to ischemia, maintaining ion gradients, and the preconditioning of neural stem cells make it a promising therapeutic target for acute cerebral ischemia. Recent advances in high-throughput screening have enabled the identification of small molecules that can upregulate SUMOylation, some of which have been validated in pertinent preclinical models of cerebral ischemia. Accordingly, the present review aims to summarize current knowledge and highlight the translational potential of the SUMOylation pathway in brain ischemia. |
format | Online Article Text |
id | pubmed-10221934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102219342023-05-28 SUMOtherapeutics for Ischemic Stroke Karandikar, Paramesh Gerstl, Jakob V. E. Kappel, Ari D. Won, Sae-Yeon Dubinski, Daniel Garcia-Segura, Monica Emili Gessler, Florian A. See, Alfred Pokmeng Peruzzotti-Jametti, Luca Bernstock, Joshua D. Pharmaceuticals (Basel) Review The small, ubiquitin-like modifier (SUMO) is a post-translational modifier with a profound influence on several key biological processes, including the mammalian stress response. Of particular interest are its neuroprotective effects, first recognized in the 13-lined ground squirrel (Ictidomys tridecemlineatus), in the context of hibernation torpor. Although the full scope of the SUMO pathway is yet to be elucidated, observations of its importance in managing neuronal responses to ischemia, maintaining ion gradients, and the preconditioning of neural stem cells make it a promising therapeutic target for acute cerebral ischemia. Recent advances in high-throughput screening have enabled the identification of small molecules that can upregulate SUMOylation, some of which have been validated in pertinent preclinical models of cerebral ischemia. Accordingly, the present review aims to summarize current knowledge and highlight the translational potential of the SUMOylation pathway in brain ischemia. MDPI 2023-04-29 /pmc/articles/PMC10221934/ /pubmed/37242456 http://dx.doi.org/10.3390/ph16050673 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Karandikar, Paramesh Gerstl, Jakob V. E. Kappel, Ari D. Won, Sae-Yeon Dubinski, Daniel Garcia-Segura, Monica Emili Gessler, Florian A. See, Alfred Pokmeng Peruzzotti-Jametti, Luca Bernstock, Joshua D. SUMOtherapeutics for Ischemic Stroke |
title | SUMOtherapeutics for Ischemic Stroke |
title_full | SUMOtherapeutics for Ischemic Stroke |
title_fullStr | SUMOtherapeutics for Ischemic Stroke |
title_full_unstemmed | SUMOtherapeutics for Ischemic Stroke |
title_short | SUMOtherapeutics for Ischemic Stroke |
title_sort | sumotherapeutics for ischemic stroke |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221934/ https://www.ncbi.nlm.nih.gov/pubmed/37242456 http://dx.doi.org/10.3390/ph16050673 |
work_keys_str_mv | AT karandikarparamesh sumotherapeuticsforischemicstroke AT gerstljakobve sumotherapeuticsforischemicstroke AT kappelarid sumotherapeuticsforischemicstroke AT wonsaeyeon sumotherapeuticsforischemicstroke AT dubinskidaniel sumotherapeuticsforischemicstroke AT garciaseguramonicaemili sumotherapeuticsforischemicstroke AT gesslerfloriana sumotherapeuticsforischemicstroke AT seealfredpokmeng sumotherapeuticsforischemicstroke AT peruzzottijamettiluca sumotherapeuticsforischemicstroke AT bernstockjoshuad sumotherapeuticsforischemicstroke |